New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 26, 2014
08:02 EDTABBVAbbVie initiates Phase 3 study of Veliparib for advanced breast cancer
AbbVie initiated a Phase III clinical trial evaluating the safety and efficacy of its investigational compound, veliparib, when added to carboplatin and paclitaxel, two chemotherapeutic medicines, in patients with advanced breast cancer. The randomized, double-blind, Phase III clinical trial will recruit approximately 270 patients. The primary efficacy outcome of the trial is progression-free survival. The secondary pre-specified outcome measures include overall survival, clinical benefit rate, objective response rate and duration of response.
News For ABBV From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 8, 2015
06:24 EDTABBVBiogen and AbbVie's Zinbryta for MS improved cognitive results in Phase 3 study
Subscribe for More Information
October 7, 2015
07:36 EDTABBVInfectious Diseases Society of America to hold a conference
Subscribe for More Information
07:23 EDTABBVEuropean Committee Treatment & Research in Multiple Sclerosis holds meeting
Subscribe for More Information
October 1, 2015
13:14 EDTABBVEnanta says 34 abstracts from AbbVie chronic hep C program to be presented
Subscribe for More Information
13:04 EDTABBVAbbVie to present 34 abstracts from hep C program at The Liver Meeting 2015
Subscribe for More Information
September 30, 2015
09:12 EDTABBVInfinity Pharma reaches $130M milestone payment from AbbVie for duvelisib
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use